FILE:STJ/STJ-8K-20121205081518.txt.gz
EVENTS:	Regulation FD Disclosure	Financial Statements and Exhibits
TEXT:
ITEM: Regulation FD Disclosure
ITEM: Financial Statements and Exhibits
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
FORM 8-K
 
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  
December 5, 2012
 
ST. JUDE MEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
 
Registrants telephone number, including area code:  
(651) 756-2000
 
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
Item 7.01  Other Events.
 
On November 29, 2012, St. Jude Medical, Inc. (the Company) announced that its Board of Directors had authorized a share repurchase of up to $1 billion of its outstanding common stock. The Company intends to commence the share repurchases in the near future through a 10b5-1 Trading Plan.
 
Prior to entering into the 10b5-1 Trading Plan, the Company is hereby reaffirming its fourth quarter and full year 2012 sales by product category and earnings per share guidance. For convenience, the previously-issued sales expectations (by product category) and earnings per share guidance can be found in Exhibit 99.1 to this report.
 
 
Item 9.01  Financial Statements and Exhibits.
 
(d) Exhibits:
 
99.1            Previously-issued Sales Expectations and Earnings Guidance
 
 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
EXHIBIT INDEX
 
 
 
 
 
 
 
 
 
 
 
 

Exhibit 99.1
 
 
Revenue (by product category):
 
 
 
Earnings:
 
The Company expects its adjusted diluted net earnings per share for the fourth quarter to be in the range of $0.86-$0.88 and its adjusted diluted net earnings per share for full year 2012 to be in the range of $3.42 -$3.44.
 
 
2012 Earnings Guidance Reconciliation
 
 
 
 
Forward-Looking Statements
This exhibit contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon managements current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Companys control and the risk factors and other cautionary statements described in the Companys filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2012. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
 
 


